Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10185767 | 0.99 | HRH3 (0.44) | HRH3DGAT1MAPTNPC1RAB9A | |
| SCHEMBL10186506 | 0.92 | HRH3 (0.45) | HRH3DGAT1ARSOAT1FFAR4 | |
| SCHEMBL10184973 | 0.90 | HRH3 (0.44) | HRH3MAPTARALDH1A1ALOX15 | |
| SCHEMBL10186471 | 0.90 | DGAT1 (0.48) | HRH3DGAT1SOAT1 | |
| SCHEMBL10185751 | 0.89 | HRH3 (0.44) | HRH3DGAT1MAPTALDH1A1ALOX15 | |
| SCHEMBL10186112 | 0.89 | HRH3 (0.44) | HRH3MAPTNPC1RAB9AAR | |
| SCHEMBL10185079 | 0.88 | HRH3 (0.53) | HRH3DGAT1MAPTRAB9AALDH1A1 | |
| SCHEMBL10185745 | 0.88 | HRH3 (0.44) | HRH3DGAT1MAPTNPC1RAB9A | |
| SCHEMBL10186257 | 0.88 | HRH3 (0.53) | HRH3DGAT1MAPTALDH1A1ALOX15 | |
| SCHEMBL10185386 | 0.87 | RXFP1 (0.43) | HRH3MAPTNPC1RAB9AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | HRH3 2422/4885DGAT1 1/4885MAPT 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.